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Abstract
Background: There are several methods of assessing nutritional status in cancer of which serum albumin is one of
the most commonly used. In recent years, the role of malnutrition as a predictor of survival in cancer has received
considerable attention. As a result, it is reasonable to investigate whether serum albumin has utility as a prognostic
indicator of cancer survival in cancer. This review summarizes all available epidemiological literature on the
association between pretreatment serum albumin levels and survival in different types of cancer.
Methods: A systematic search of the literature using the MEDLINE database (January 1995 through June 2010) to
identify epidemiologic studies on the relationship between serum albumin and cancer survival. To be included in
the review, a study must have: been published in English, reported on data collected in humans with any type of
cancer, had serum albumin as one of the or only predicting factor, had survival as one of the outcome measures
(primary or secondary) and had any of the following study designs (case-control, cohort, cross-sectional, case-series
prospective, retrospective, nested case-control, ecologic, clinical trial, meta-analysis).
Results: Of the 29 studies reviewed on cancers of the gastrointestinal tract, all except three found higher serum
albumin levels to be associated with better survival in multivariate analysis. Of the 10 studies reviewed on lung
cancer, all excepting one found higher serum albumin levels to be associated with better survival. In 6 studies
reviewed on female cancers and multiple cancers each, lower levels of serum albumin were associated with poor
survival. Finally, in all 8 studies reviewed on patients with other cancer sites, lower levels of serum albumin were
associated with poor survival.
Conclusions: Pretreatment serum albumin levels provide useful prognostic significance in cancer. Accordingly,
serum albumin level could be used in clinical trials to better define the baseline risk in cancer patients. A critical
gap for demonstrating causality, however, is the absence of clinical trials demonstrating that raising albumin levels
by means of intravenous infusion or by hyperalimentation decreases the excess risk of mortality in cancer.
Introduction
Cancer is a major public health problem in the United
States (US) and many other parts of the world. The
World Health Organization (WHO) estimates that by
2020, globally, more than 15 million people will experi-
ence cancer and 10 million will die from it each year
[1]. With the changing trends and advances in diagnos-
tic aids, cancers can be diagnosed at much early age.
Several important prognostic factors have been
identified in the literature, some generic to all cancers
and some specific for different cancer types. Some of
the key factors determining cancer survival are age,
stage [2,3], number of metastatic sites involved [4], loca-
tion of metastases, tachycardia, blood counts [5,6],
tumor markers [7,8], performance status (PS) [9,10],
quality of life and malnutrition [11,12].
Malnutrition and cachexia in cancer patients are sig-
nificant problems due to a variety of mechanisms invol-
ving the tumor, the host response to the tumor, and
anticancer therapies [13]. Malnutrition has been asso-
ciated with a number of clinical consequences, including
deteriorated quality of life, decreased response to
* Correspondence: Christopher.lis@ctca-hope.com
Cancer Treatment Centers of America® at Midwestern Regional Medical
Center, Zion, IL, USA
Gupta and Lis Nutrition Journal 2010, 9:69
http://www.nutritionj.com/content/9/1/69
© 2010 Gupta and Lis; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.treatment, increased risk of chemotherapy-induced toxi-
city and a reduction in cancer survival [14]. There are
various methods of assessing nutritional status in cancer,
each with its own advantages and disadvantages [15].
Among the most commonly used tools to measure
nutritional status are subjective global assessment (SGA)
[16-18], bioelectrical impedance analysis (BIA) [19], and
laboratory measurements of serum albumin [20], preal-
bumin, and transferrin [21,22]. Others include anthropo-
metric parameters [21,23,24] such as weight loss, arm
muscle circumference, skin-fold thickness [18,25], and
presence of edema and ascites [26]. Though SGA is
easy-to-use, inexpensive, and noninvasive, it is subjec-
tively assessed and hence can be affected by inter-obser-
ver variation. Similarly, though BIA is easy-to-use,
noninvasive, and reproducible, it relies on regression
models derived in restricted samples of human subjects,
which thus limits the usefulness of the derived model in
o t h e rp a t i e n t sw h od i f f e rf r o mt h eo r i g i n a ls a m p l e
[27,28].
Serum albumin provides a simple method of estimat-
ing visceral protein function. Malnutrition and inflam-
mation suppress albumin synthesis [29]. In an adult the
normal range of serum albumin is defined as 3.5-5.0 g/
dL and levels <3.5 g/dL is called hypoalbuminemia
[2,3]. The inverse correlation between body weight
index and albumin synthesis in cancer patients supports
t h ep o s s i b i l i t yo fac o m p e n s a t o r ye n h a n c e da l b u m i n
synthesis in these metabolically affected patients. In the
later stages of disease, malnutrition and inflammation
suppress albumin synthesis [30]. As part of the systemic
inflammatory response to the tumor, proinflammatory
cytokines and growth factors are released [31,32] and
have a profound catabolic effect on host metabolism.
Interleukin-6, produced by the tumor or surrounding
cells, stimulates liver production of acute-phase reaction
proteins (such as C-reactive protein (CRP) and fibrino-
gen) in both the fasted and fed states. This increases
the demand for certain amino acids, which if limited in
the diet, may be obtained from breakdown of skeletal
muscle. The lower serum albumin concentration may
be due to the production of cytokines such as IL-6,
which modulate the production of albumin by hepato-
cytes [33]. Alternatively, tumor necrosis factor may
increase the permeability of the microvasculature, thus
allowing an increased transcapillary passage of albumin.
Presence of micrometastatic tumor cells in liver may
induce the kupffer cells to produce a variety of cyto-
kines (IL-Ib, IL-6 ve TNF), which may modulate albu-
min synthesis by hepatocytes [33,34]. Thus there is
slight or no hypoalbuminemia in early stages of cancer
but as the disease progresses albumin levels drop signif-
icantly and serve as good indicators of prognosis of can-
cer [33,34].
Serum albumin is generally used to assess the nutri-
tional status, severity of disease, disease progression and
prognosis. In the hospital setting, many reports have
related serum albumin level to in-hospital mortality
[35-38], length of stay (LOS) [39-41], and nosocomial
infection [36,42]. Serum albumin has also been
described as an independent prognosticator of survival
in various cancers [43] like lung [12], pancreatic [6], gas-
tric [44], colorectal [7,8,45] and breast [46]. Low serum
albumin has also been shown to be an independent indi-
cator for prognosis in cancer patients with unknown
primaries [47]. However, these studies differ from each
other with regard to population studied, study design,
sample size, definition of low serum albumin used and
factors adjusted for in the analyses. We therefore
reviewed all available epidemiological literature (pub-
lished within the last 15 years) to summarize the role of
pretreatment serum albumin as an independent predic-
tor of survival in cancer.
Methods
We performed a systematic search of the literature using
the MEDLINE database (January 1995 through June
2010) to identify epidemiologic studies on the relation-
ship between serum albumin and cancer survival. We
searched using the terms ‘’cancer survival or mortality
or prognosis” in combination with the following terms:
serum albumin, nutrition, serum proteins, predictors,
and risk factors. We also searched the bibliography of
the selected papers to identify relevant articles that we
might have missed during the primary MEDLINE
search. To be included in the review, a study must have:
been published in English, reported on data collected in
humans with any type of cancer, had serum albumin as
one of the or only predicting factor, had survival as one
of the outcome measures (primary or secondary) and
had any of the following study designs (case-control,
cohort, cross-sectional, case-series prospective, retro-
spective, nested case-control, ecologic, clinical trial,
meta-analysis). There were no restrictions according to
age, ethnicity or stage of cancer. As we were interested
in empirical reports that have investigated the relation-
ship between serum albumin and cancer survival, we did
not include letters and meeting abstracts. All studies
reviewed in this paper have been summarized in tables
under separate headings by cancer type. This was pri-
marily done to enable meaningful conclusions to be
drawn separately for different cancer types as well as
also to categorize studies into roughly equal groups.
Within each table, studies were arranged chronologically
by the year of publication starting with the most
recently published study.
Although we did not formally rate the quality of
reports, we recorded and present information on
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variables include study design, years of data collection,
sample size, serum albumin cut-offs used, estimate of
the association between serum albumin and cancer sur-
vival and inclusion of important prognostic factors in
multivariate analyses.
Results
The MEDLINE search identified 735 studies, which
were assessed for relevance. Of these 735 studies, 175
studies were selected, and their abstracts were assessed
for inclusion criteria by the authors. This exercise left
59 studies for the purpose of final inclusion and review
in this manuscript.
Gastrointestinal Cancer
Table 1 describes studies investigating the relationship
between serum albumin and cancer survival in gastroin-
testinal cancer. The studies are arranged chronologically
by the year of publication.
A study evaluating the influence of the modified Glas-
gow Prognostic Score (GPS) for prognostication of
patients undergoing chemotherapy for unresectable col-
orectal cancer found it to be a an independent predictor
of survival [48]. A study conducted to determine the
prognostic value of pre-operative systemic inflammatory
biomarkers and socioeconomic deprivation in patients
undergoing resection of colorectal liver metastases
found poor clinical risk score (3-5), high neutrophil
count (>6.0 × 10(9)/l) and low serum albumin (<4 g/dL)
to be the only independent predictors [49]. A study con-
ducted in patients with colorectal cancer undergoing
surgical treatment identified low serum albumin level,
advanced Union for International Cancer Control
(UICC) stage, and high carcinoembryonic antigen (CEA)
level to be independent prognostic factors of cancer-spe-
cific survival [50]. A study done to evaluate if CRP and
serum albumin were survival predictors of esophageal
cancer demonstrated that only serum CRP concentra-
tion and hypoalbuminemia were independent prognostic
indicators of survival [51]. A study analyzed the prog-
nostic factors for survival after recurrence in hepatocel-
lular carcinoma (HCC) and found that early recurrence
(< or =12 months), Child-Pugh class B or C at diagnosis
of recurrence, and serum albumin level of < or =3.5 g/
dL at diagnosis of recurrence were poor prognostic fac-
tors for survival [52]. A study assessing the prognostic
predictors in patients with HCC after radiofrequency
ablation found low serum albumin, a high level of pro-
thrombin induced by vitamin K absence or antagonist II
(PIVKA-II), and multiple nodules to be independently
prognostic of survival [53]. A study assessing the impact
of baseline nutritional status on treatment response and
survival in nonmetastatic patients with a locally
advanced esophageal cancer treated with definitive che-
moradiotherapy (CRT) found that in multivariate analy-
sis, serum albumin level >3.5 g/dL was the only
independent predictive factor of complete response to
CRT (P = 0.009). However, for survival, independent
prognostic factors were body mass index (BMI) >18 kg/
m2, dysphagia Atkinson score, dose of RT >50 Grays
and complete response to CRT [2]. Another study inves-
tigating the significance of preoperative GPS, that
includes only serum CRP and serum albumin for post-
operative prognostication ofp a t i e n t sw i t hc o l o r e c t a l
cancer found that upon multivariate analyses using fac-
tors such as age, sex, tumor site, serum CEA, CA19-9,
CA72-4, CRP, albumin, and GPS revealed that GPS was
associated with postoperative mortality [3]. A study
determined clinical and laboratory predictors of mortal-
ity in pancreatic cancer and found that upon multivari-
ate analysis low serum albumin and an increased white
blood cell (WBC) count independently predicted survi-
val of less than 6 months [6].
Another study conducted to define the prognostic role
of serum albumin in gastric cancer found that categor-
ized pre-therapeutic serum albumin groups (medium,
low and very low albumin) presented median survival
t i m e so f1 . 4 4y e a r s ,1 . 9 6y e a r sa n d2 . 6 2y e a r sr e s p e c -
tively while the group of high albumin presented a
mean survival of 10.68 years (P < 0.001). Multivariate
analysis indicated that TNM staging system, surgical
resection, type of lymph node dissection, gender and
serum albumin were significant prognostic factors [44].
A study found that a combination of an elevated CRP
and hypoalbuminaemia (GPS) was significantly asso-
ciated with overall and cancer specific survival in color-
ectal cancer [54]. A study investigating the relationship
between the serum levels of high sensitivity CRP (H-
CRP) and the prognosis of HCC patients found positive
H-CRP, albumin, tumor stage and initial treatment to
be significant independent determinants of poor prog-
nosis [55]. Another study evaluated novel inflammatory
and nutritional prognostic factors in patients with
advanced colorectal cancer. Using univariate analysis,
significantly worse survival was found for patients with
poorer performance status, high GPS, low albumin, ele-
vated serum alkaline phosphatase (ALP), patient-gener-
ated subjective global assessment (PGSGA) score of >9.
Upon multivariate analysis, type of treatment, PS, GPS,
and ALP remained significant predictors of survival [56].
A study investigating whether nutritional factors could
predict survival in oral cancer found upon multivariate
analysis that those with a preoperative BMI of <22.8 kg/
m2 tended to have a higher probability of death. In
addition, those with a preoperative serum albumin level
of <4.15 g/dL were generally associated with a poorer
prognosis [57].
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First author, year
of publication,
place
Year of
data
collection
Study
design,
Sample size
Cancer type Groups
being
compared
RR (95%Cl), p-value Variables adjusted for
Ishizuka M, 2009,
Japan [48]
April 2005
to July
2007
Retrospective,
112
Colorectal <3.5 g/dL
>=3.5 g/dL
Univariate: 1.37
(1.10-1.71), 0.004
Multivariate: 2.38
(0.73-7.78), 0.14
Age, sex, tumor site, aspartate
transaminase (AST), alanine transaminase
(ALT), WBC, neutrophil, CA 19-9, CA 72-4,
CRP
Neal CP, 2009, UK
[49]
January
2000 to
December
2005
Retrospective,
174
Colorectal <4 g/dL
>=4 g/dL
Univariate: 1.98
(1.21-3.25) 0.007
Multivariate: 1.68
(1.01-2.79) 0.04
Age, sex, site, stage, CEA, liver mets,
chemotherapy, hematological indices,
clinical risk score, Carstairs deprivation
index
Sun LC, 2009,
Taiwan [50]
January
1996 to
December
2006
Retrospective
cohort, 1367
Colorectal <3.5 g/dL
>=3.5 g/dL
Univariate: 1.72(1.38-
2.14) < 0.001
Multivariate: 1.45(1.09-
1.92) 0.011
Age, sex, site, tumor size, BMI, histology,
UICC stage, CEA
Wang CY, 2009,
Taiwan [51]
November
2002 to
July 2007
Prospective,
123
Esophageal >=3.5 g/dL
<3.5 g/dL
Also used
as
continuous
variable
Univariate: p < 0.001
Multivariate:
Categorical = 3.9,
(1.9-8.2), <0.001
Continuous = 0.38,
(0.25-0.58), <0.001
Age, histology, tumor location, stage,
Serum CRP, BMI, WBC count, platelet,
bilirubin, hemoglobin, BMI, treatment
modality
Choi GH, 2008,
South Korea [52]
March
1998 to
January
2005
Retrospective,
97
Hepatocellular <3.5 g/dL
>=3.5 g/dL
Multivariate: 4.59
(1.79-11.75), 0.001
Sex, cirrhosis, AFP, platelets, tumor size,
number of tumors, intrahepatic mets,
venous invasion, Child-Pugh class, time
to recurrence
Takahashi S, 2008,
Japan [53]
March
1999 to
September
2004
Retrospective
cohort, 179
Hepatocellular <3.5 g/dL
>=3.5 g/dL
Univariate: p = 0.001
Multivariate: 3.75(1.64-
8.56) 0.002
Age, sex, bilirubin, platelets, AFP, PIVKA-II,
tumor size, tumor nodules
Di Fiore FD, 2007,
France [2]
January
1997 to
December
2003
Retrospective,
consecutive
case series,
105
Non-
metastatic
esophageal
<=3.5 g/dL
>3.5 g/dL
Univariate: p = 0.007
Multivariate: 0.99
(0.50-1.98), 0.99
Age, sex, performance status, weight
loss, BMI, hemoglobin, tumor location,
tumor length, stage of disease,
radiotherapy dose
Ishizuka M, 2007,
Japan [3]
January
2001 to
March
2006
Retrospective,
315
Colorectal <=3.5 g/dL
>3.5 g/dL
Univariate: 0.85
(0.53-1.343), 0.488
Multivariate: 1.98
(0.91-4.29), 0.082
Age, sex, tumor site, CEA, CA19-9, CA72-
4, CRP, GPS
Siddiqui A, 2007,
USA [6]
July 1986
to
December
2004
Retrospective,
69
Pancreas >=3.5 g/dL
<3.5 g/dL
Univariate: p < .0001
Multivariate: 2.98 (2.20
to 3.76), <.0001
CA19-9, WBC, laboratory indicators,
co-morbidities, age, sex, BMI, stage,
treatment
Onate-Ocana LF,
2007, Mexico [44]
January
1987 to
December
2002
Retrospective,
1023
Gastric High:
>=3.77 g/
dL
Medium:
3.3 to 3.73
g/dL
Low: 2.81
to 3.29 g/
dL
Very low:
<=2.3 g/dL
Medium: 1.2 (0.8-1.7),
0.31
Low: 1.2 (0.8-1.8), 0.31
Very low: 1.8 (1.3-2.6),
0.001
Stage of disease, lymph node dissection,
gender, surgical resection
McMillan DC, 2007,
UK [54]
January
1997 to
June 2004
Retrospective,
316
Colorectal <=3.5 g/dL
>3.5 g/dL
GPS based on CRP and
albumin was associated
with survival
(p < 0.0001)
Age, Sex, stage, adjuvant therapy
Nagaoka S, 2007,
Japan [55]
January
1997 to
November
1998
Cohort, 90 Hepatocellular <3.5 g/dL
>=3.5 g/dL
Univariate: 1.75
(1.13-2.70) 0.011
Multivariate: 2.01
(1.20-3.37) 0.008
Age, sex, hepatitis B virus, bilirubin,
prothrombin time, platelet count, CRP,
AFP, stage, initial treatment, AST, ALT
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Read JA, 2006,
Australia [56]
NA Prospective
consecutive
case series, 51
Colorectal <3.5 g/dL
>=3.5 g/dL
Univariate: p = 0.017
Median survival in
months
>=3.5 g/dL = 14.3
<3.5 g/dL = 10.3
Gender, age, extent of prior therapy,
extent of disease, PS, liver
function CRP, PG-SGA, GPS, type of
treatment
Liu SA, 2006, Taiwan
[57]
March
1995 to
December
2002
Retrospective,
1010
Oral >=4.15 g/
dL
<4.15 g/dL
Multivariate: 1.313,
(1.052-1.638), 0.016
Age, sex, complications, BMI, stage,
recurrence/metastasis
Boonpipattanapong,
T, 2006, Thailand [7]
October 1,
1998 to
October 31,
2002
Retrospective
cohort, 172
Colorectal <3.5 g/dL
>=3.5 g/dL
5-year survival
<3.5 g/dL = 48%
>=3.5 g/dL = 59%
CEA, tumor differentiation
Cengiz O, 2006,
Turkey and USA [8]
1994-2003 Retrospective,
99
Colorectal <=3.5 g/dL
>3.5 g/dL
Univariate: <0.0001
Multivariate: 2.791,
(1.37-5.67), 0.005
Age, gender, location, differentiation,
hemoglobin, cholesterol, TNM stage,
venous invasion, CEA, metastasis
Alici S, 2006, Turkey
[58]
September
1999 to
April 2002
Retrospective,
138
Gastric <3 g/dL
>=3 g/dL
Univariate:
Median survival in years
<3 g/dL: 1.7
>=3 g/dL: 8.8 p = 0.006
BMI, clinical stage, surgery, type of
surgery, gender, age, PS, tumor grade,
tumor location, hemoglobin. LDH, type
of surgery
Arimura E, 2005,
Japan [59]
January
1988 to
December
2002
Prospective
consecutive
case series,
140
Hepatocellular <=3.5 g/dL
>3.5 g/dL
Univariate: 1.69
(1.01-2.84), 0.04
Multivariate: 1.49
(0.76-2.90), 0.24
LFTs, tumor size, tumor number, local
recurrence, distant recurrence, AFP, ICG-
R15 (%)
Schindl M, 2005, UK
[60]
October 1,
1988, to
January
31, 2002
Retrospective,
337
Colorectal Continuous
variable
Univariate: p < 0.001
Multivariate: 0.9 (0.9-1.0)
p < 0.001
Dukes stage, site of primary tumor,
diameter of the largest liver lesion,
serum CEA, ALP, number of lesions,
bilobar disease, age
Tateishi R, 2005,
Japan [61]
January
1990 to
December
1997
Prospective
consecutive
case series,
403
Hepatocellular >3.5 g/dL
(reference)
2.8-3.5 g/dL
<2.8 g/dL
Univariate:
1.99 (1.52-2.59),0.0001
3.13 (2.01-4.88),0.0001
Multivariate:
1.74 (1.31-2.30) 0.00014
2.45 (1.55-3.88) 0.00013
Age, sex, treatment modality, tumor
factors, including size, number of
nodules, lobar distribution, and presence
of extrahepatic metastasis, clinical
manifestations, including ascites and
hepatic encephalopathy, bilirubin,
prothrombin activity, AST, ALT, platelet
count, AFP, positivity for viral markers
(hepatitis B surface antigen and anti-
hepatitis C antibody), alcohol
Xu HX, 2005, China
[62]
August
1997 to
September
2003
Prospective
consecutive
case series,
137
Hepatocellular <3.5 g/dL
>=3.5 g/dL
Multivariate: 0.48
(0.28-0.83), 0.008
Age, gender, cirrhosis, Child’s class, AFP,
ALT, bilirubin, prothrombin time, tumor
nodules, tumor size, treatment method,
recurrence
Lien YC, 2004,
Taiwan [63]
1987 to
1997
Retrospective,
314
Gastric cardia >3.5 g/dL
<=3.5 g/dL
Univariate: 5 year
survival rate
>3.5 g/dL: 38.4%
<=3.5 g/dL: 19.1%,
p = <0.001
Age, sex, extent of resection, diet at
presentation, depth of penetration,
nodal involvement
Elahi MM, 2004, UK
[64]
1988 to
1996
Retrospective,
165
Colorectal
Gastric
<3.5 g/dL
>=3.5 g/dL
Median survival in
months
<3.5 g/dL: 1.7(0.6-2.8),
>=3.5 g/dL: 6.9 (4.7-9.0)
p = <0.001
Age, sex, GPS, tumor type, CRP
Chen MF, 2003,
Taiwan [65]
1986 to
1998
Retrospective,
254
Hepatocellular <=3.5 g/dL
>3.5 g/dL
Univariate:
Median survival in
months
<=3.5 g/dL: 6.18
>3.5 g/dL: 12.3,
p = 0.0037
Multivariate:
Disease-free survival
2.17 (1.21-3.90)
Overall survival 1.65
(1.005-2.73)
Age, sex, Hepatitis B antigen, Hepatitis C
antibody, AFP, BUN, creatinine, ALP, AST,
bilirubin, prothrombin time, extent of
resection, blood loss, blood transfusion,
tumor size, no of tumors, resection
margin, operating time
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preoperative CEA level greater than or equal to 5 ng/
mL and albumin level less than 3.5 g/dL predict a poor
survival chance for colorectal carcinoma patients. [7].
Another study investigating if pretreatment serum albu-
min and cholesterol levels were prognostic factors in
patients with colorectal carcinomas concluded that a
preoperative low level of serum albumin can be an indi-
cator for the malignant potential of the tumor and
represents an unfavorable prognosis for patients with
colorectal carcinoma [8]. A study evaluated the effects
of clinicopathological parameters and treatment
approaches on survival in gastric carcinoma. With single
variable analysis, BMI, clinical stage, surgery, type of
surgery, and serum albumin were significant prognostic
factors related to overall median survival time while on
multivariate analysis, no surgical treatment, palliative
surgery (compared with radical surgery), and BMI below
20 kg/m2 were found to be the statistically significant
poor prognostic factors related to survival in multiple
variable analysis [58].
A study conducted in 140 previously untreated cases
of HCC found the indocyanine green retention at 15
min (ICG) test, tumor size, tumor number, and local
recurrence to be the significant prognostic factors of
survival upon multivariate analysis [59]. Another study
in 337 patients with colorectal cancer liver metastases
found Dukes stage, number of metastases, and serum
concentrations of CEA, ALP, and albumin to be inde-
pendent predictors of survival [60]. A study conducted
in 403 patients with HCC found serum albumin,
bilirubin, size of the tumor, and number of tumor
nodules to be independent predictors of survival [61]. A
study to identify prognostic factors for long-term out-
come for patients with HCC after percutaneous micro-
wave or radiofrequency ablation found incomplete
ablation, serum albumin level, serum alpha-fetoprotein
(AFP) level and Child-Pugh classification to be indepen-
dent predictors of survival [62]. A study evaluating
serum albumin as a prognostic factor for patient survival
in cancer of gastric cardia found that in each cancer
stage, the 5-year survival rate of patients with normal
serum albumin levels was better than that among those
with hypoalbuminemia. By multivariate analysis, serum
albumin level and the pathologic T, N statuses were
independent factors correlated with prognosis [63]. A
study was done to assess the value of combination of
hypoalbuminemia and an elevated circulating concentra-
tion of CRP as a prognostic score in patients with
advanced gastrointestinal cancer and found that a
cumulative score based on these two parameters was a
useful prognostic indicator [64]. Another study investi-
gated the prognostic factors in HCC patients without
cirrhosis who underwent hepatectomy. By Cox regres-
sion analysis, serum ALP, albumin, multiple tumor sta-
tus, and blood urea nitrogen were shown to be
independent prognostic factors for the 5-year disease-
free survival rates while serum albumin, blood transfu-
sion, resection margin, and multiple tumors were shown
to be significant independent factors that influenced
overall survival rates [65]. Another study was done to
clarify the factors contributing to the survival of HCC
Table 1: Serum albumin and survival - gastrointestinal cancer (Continued)
Koike Y, 2003, Japan
[66]
1987 to
1999
Retrospective
consecutive
case series,
952
Hepatocellular NA Univariate analysis
indicated that the
serum albumin level
was associated with
survival
Child classification, number of tumor
foci, portal venous invasion-targeted
irradiation, and percutaneous tumor
ablation of the parenchymal main tumor
Dixon MR, 2003, USA
[67]
1991-1999 Retrospective
cohort, 105
Colorectal Continuous
variable
Univariate (Median
Albumin) (IQR):
Short survival <120
days : 2.5 (2.2-3.0)
Long survival >120
days : 3.1 (2.6-3.5), 0.002
Age, ALP, AST, total bilirubin, CEA, ALT,
prothrombin time, mean corpuscular
volume,
fibrinogen, hematocrit, creatinine
Heys SD, 1998, UK
[45]
1972 to
1985
Retrospective
case series,
431
Colorectal Continuous
variable
Univariate: <0.00005
Multivariate: 0.95 (0.93-
0.98) < 0.0001
Duke’s stage, age and tumor
differentiation
Stuart KE, 1996, USA
[68]
1986-1995 Retrospective,
314
Hepatocellular Albumin
cutoffs not
provided
Univariate:
Median survival in
months
Low albumin: 4
High Albumin: 15,
p < 0.001
Multivariate: p < 0.001
Age, gender, cirrhosis, alcohol abuse,
bilirubin, PVO and AFP
Onate-Ocana LF,
2007, Mexico [69]
NA Retrospective
cohort, 793
Gastric <=3.5 g/dL
>3.5 g/dL
Multivariate: 1.26
(1.03-1.5), <0.03
TNM stage, operative morbidity, type of
lymphadenectomy, gastrectomy
performed
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indicated that the serum albumin level, Child classifica-
tion, number of tumor foci, portal venous invasion-
targeted irradiation, and percutaneous tumor ablation of
the parenchymal main tumor were significant. Multivari-
ate analysis showed that percutaneous tumor ablation
was the most important factor contributing to a favor-
able prognosis followed by number of tumor foci [66].
Another study found that patients with stage IV colon
and rectal cancer with a CEA level greater than or equal
to 275 ng/mL and an albumin level less than 2.7 g/dL
had a significantly shorter survival time. Conversely,
patients with an albumin level greater than or equal to
2.7 g/dL and a CEA level less than 275 ng/mL had a
longer survival time [67]. A study investigated the prog-
nostic value of serum albumin in colorectal cancer
patients and found serum albumin, age, tumor stage
(Dukes’ stage) and tumor differentiation to be indepen-
dent prognostic factors for survival [45]. Another study
investigated prognostic factors at presentation in
patients with HCC. Univariate analysis demonstrated
t h a ts e r u ma l b u m i n ,c i r r h o s i s ,A F P ,a n dp o r t a lv e i n
obstruction (PVO) were prognostic factors of high sta-
tistical significance. Multiple regression analysis yielded
albumin, AFP, and PVO as the most powerful indepen-
dent negative predictors of ultimate survival [68]. A
study conducted in 793 patients with gastric cancer
found TNM stage, operative morbidity, serum albumin,
age, type of lymphadenectomy and gastrectomy per-
formed to be independent prognostic factors [69].
A great majority of the studies reported in this section
were retrospective and conducted in patients with color-
ectal cancer. The studies reviewed above highlight the
importance of pretreatment serum albumin as an inde-
pendent predictor of survival in patients with gastroin-
testinal cancer.
Lung Cancer
Table 2 describes studies investigating the relationship
between serum albumin and cancer survival in lung can-
cer. The studies are arranged chronologically by the year
of publication.
As t u d yw a sd o n et oi d e n t i f yp r o g n o s t i cf a c t o r si n
patients with potentially curable lung cancer. Factors sig-
nificantly (p < 0.05) associated with poor overall survival
were age at assessment, diabetes, serum albumin, peak
VO2 max, shuttle walk distance, and predicted postopera-
tive transfer factor [70]. The value of an inflammation-
based prognostic score (GPS) was compared with PS in a
longitudinal study of patients with inoperable non small
cell lung cancer (NSCLC). At diagnosis, stratified for treat-
ment, only the GPS (Hazard Ratio (HR) 2.32, 95% Confi-
dence Interval (CI) 1.52-3.54, P < 0.001) was a significant
predictor of survival. In contrast, neither the GPS nor PS
measured at 3-6 months follow-up were significant
predictors of residual survival [71]. Another study analyzed
prognostic factors in patients with advanced NSCLC who
had been enrolled in clinical trials conducted by the
Okayama Lung Cancer Study Group. PS, clinical stage,
liver metastasis or serum albumin level was an indepen-
dent prognostic factor by Cox’sa n a l y s i s[ 9 ] .As t u d yw a s
conducted to investigate the distribution of metastatic
lesions and their influence on survival, as well as other
prognostic factors on the outcome of patients with exten-
sive small cell lung cancer (SCLC). Response to treatment
was the most important prognostic factor; while clinical
stage, weight loss, performance status, gender and serum
lactate dehydrogenase (LDH) and albumin levels were
other relevant parameters in predicting the outcome of
patients with SCLC (p = 0.05) [10].
A study was done to determine predictive factors of
treatment response and survival in SCLC and NSCLC.
In SCLC, the significant determinants of poor survival
were lack of complete response (HR: 2.04), weight loss
(HR: 1.76), high serum LDH level (HR: 1.64), and high
s e r u mT P Sl e v e l( H R :2 . 4 7 ) .I nN S C L C ,s i g n i f i c a n t
determinants of poor survival were no objective
response (HR: 2.28), poor performance status (HR:
2.52), presence of metastases (HR: 1.51), and high serum
CYFRA 21-1 level (HR: 1.84) [4]. A study conducted to
assess the impact of nutritional status on survival in
lung cancer found that patients who died within six
months after diagnosis had significantly lower values of
all nutritional parameters than those who survived more
than six months. Patients with more abnormal para-
meters tended to have poorer survival rates [72].
Another retrospective analysis was done to identify
which pretreatment clinical or blood parameters were
predictive of patient survival in small-cell lung cancer
(SCLC). Significant prognostic factors for survival after
univariate and multiple regression analysis were: disease
extent, PS, creatine kinase, neutrophilia, LDH, hypoalbu-
minemia, hyperglycemia and bicarbonate [73].
A group of consecutive patients with NSCLC was stu-
died and the prediction of their physicians as to how
long they would survive (in months) was compared with
their actual survival. A prognostic index was also devel-
oped using features recorded at the patients’ initial pre-
sentation. Using Cox’s regression model, the sex of the
patient, the activity score, the presence of malaise, hoar-
seness and distant metastases at presentation, and lym-
phocyte count, serum albumin, sodium and ALP levels
were all identified as useful prognostic factors [74].
Another study assessed the influence on survival of 21
clinical, anatomical, hematological and biochemical fac-
tors in 411 patients with advanced NSCLC. The main
determinants of survival were found to be performance
status, weight loss and serum albumin. Other factors
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lymphocytes, lactic dehydrogenase and hoarseness were
also significant [75]. A study was done with an objective
to find factors related to response, the duration of
response and overall survival in patients with advanced
NSCLC. The following factors were predictive for survi-
val: weight loss, performance status, lymphocyte count,
albumin level, number of metastases and the presence
of bone metastases. It concluded that the albumin level
identifies a group of patients with advanced NSCLC
who are more likely to respond to cisplatin-containing
chemotherapy [76].
Studies reported in this section were primarily con-
ducted in patients with NSCLC and demonstrate the
prognostic significance of pretreatment serum albumin
in predicting patient survival.
Female Cancers
Table 3 describes studies investigating the relationship
between serum albumin and cancer survival in female
Table 2 Serum albumin and survival - lung cancer
First author,
year of
publication,
place
Year of
data
collection
Study design,
Sample size
Cancer
type
Groups
being
compared
RR (95%Cl), p-value Variables adjusted for
Win T, 2008,
UK [70]
2 years up
to
December
2006
Prospective
consecutive case
series, 110
Non
Small Cell
Lung
Continuous
variable
Univariate: 0.93 (0.88-0.98), 0.006 Female gender, age, pneumectomy,
chronic obstructive pulmonary
disease, Smoking, Diabetes, Coronary
disease, BMI, global quality of life
Forrest LM,
2005, UK [71]
January
2002 to
December
2003
Prospective, 101 Non
Small Cell
Lung
>=3.5 g/dL
<3.5 g/dL
Median Survival (months) (95% CI)
For >/=3.5 g/dL = 8.7 (6.9-10.5)
For <3.5 g/dL = 1.2 (0.0-2.8),
p = <0.01
Age, sex, stage, hemoglobin, WBC,
CRP, PS, GPS, treatment
Maeda T,
2000, Japan
[9]
1978-1992 Retrospective,
261
Non
Small Cell
Lung
<3.5 g/dL
>=3.5 g/dL
Median survival in months
<3.5 g/dL = 5.0
>=3.5 g/dL = 9.6; p = <0.001
Multivariate: 1.69 (1.19-2.41), 0.0037
Age, gender, histology, PS, LFTs,
Stage IV, bilirubin, CEA, liver
metastases
Tas F, 1999,
Turkey [10]
1991 to
1997
Retrospective,
207
Small Cell
Lung
Normal:
>=3.5 g/dL
Low: <3.5
g/dL
Univariate: p = <0.001
Multivariate: p = 0.03
Age, gender, performance status,
weight loss, clinical stage,
hemoglobin, LDH, response to
chemotherapy
Ray P, 1998,
France [4]
NA Retrospective, 99
patients with
SCLC and 202
patients with
NSCLC
Small cell
lung and
Non-
Small cell
lung
NA Serum albumin levels were not
found to be associated with survival
Tumor, node, metastasis status, PS,
body weight loss, WBC, serum
sodium, LDH, ALP, serum NSE,
serum TPS, and CYFRA 21-1
Lai SL, 1998,
Taiwan [72]
NA Prospective, 150 Non
Small Cell
Lung
NA Patients who died within six months
after diagnosis had significantly lower
values of all nutritional parameters
than those who survived more than
6 months
Weight/height ratio, percent of
standard triceps skin-fold thickness,
percent of standard arm muscle
circumference, transferrin, creatinine
height index and total lymphocyte
count
Maestu I,
1997, Spain
[73]
November
1981 to
January
1993
Retrospective,
341
Small cell
lung
<3.4 g/dL
>=3.4 g/dL
Univariate: 0.0057
Multivariate : coefficient = -0.3457,
p = 0.001
LDH, disease extent, CK, neutrophils,
PS, glycemia, ESR, sodium,
potassium, ALP, urea, uric acid, age
Muers MF,
1996, UK [74]
NA Retrospective
consecutive case
series, 207
Non
Small Cell
Lung
NA Prognostic Index = -0.42 × distant
metastases + 1.1 × hoarseness + 0.47
× malaise - 0.34 × immediate
treatment intent + 0.72 × lymphocyte
count + 0.94 × serum albumin + 0.62
× sodium - 0.98 × ALP
Sex, the activity score, the presence
of malaise, hoarseness and distant
metastases at presentation, and
lymphocyte count, sodium and ALP
levels
Hespanhol V,
1995,
Portugal [75]
1984 to
1990
Prospective, 411 Non
Small Cell
Lung
<3.5 g/dL
>=3.5 g/dL
Univariate: 1.92, (1.55-2.36), 0.000
Multivariate: 0.588 (0.46-0.74), 0.000
PS, Weight loss, Hoarseness, stage,
lymphocyte, LDH, sex
Espinosa E,
1995, Spain
[76]
1980-1992 Retrospective
onsecutive case
series, 292
Non
Small Cell
Lung
>=4 g/dL
<4 g/dL
Univariate: Median survival in months
For >=4 g/dL = 9 For <4 g/dL = 7,
p = 0.004; Multivariate:
Coefficient = -2.52, p = 0.0001
Number of metastases, LDH, PS,
sedimentation rate
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year of publication.
A study investigating the prognostic role of serum
albumin in patients with ovarian cancer treated in an
integrative cancer treatment setting found that every
one gm/dL increase in serum albumin was associated
with a RR of 0.39 (95% CI: 0.29 to 0.53; p < 0.001) [77].
A study investigated whether an inflammation-based
prognostic score (GPS) was associated with survival in
patients with advanced stage (stage III/IV) ovarian can-
cer. Patients with both an elevated CRP (>10 mg/l) and
hypoalbuminaemia (<3.5 g/dL) were allocated a GPS
score of 2. Patients in whom only one or none of these
biochemical abnormalities was present were allocated a
score of 1 or 0, respectively. On multivariate analysis, a
high GPS score, non-serous histology, high ALP and no
initial surgery were independent predictors of worse
overall survival [78]. A study conducted to identify peri-
operative variables predicting surgical outcome and sur-
vival among elderly women diagnosed with ovarian and
primary peritoneal cancer found that patients older than
80 years were associated with a nearly 2-fold increase
risk of mortality while those with preoperative albumin
levels ≥3.7 g/dL were associated with a 40% reduction in
mortality risk [79]. A study investigated the effect of
baseline serum albumin levels on 180 breast cancer
patients. Univariate statistical analysis found that low
levels of serum albumin adversely affected survival by a
statistically significant level for all stages of breast cancer
while Cox regression analysis found that normal levels
of albumin (>3.5 g/dL) reduced the risk of death by 72%
(p = .0033) [46]. Another study in patients of breast
cancer with secondaries in liver found that factors that
significantly predicted a poor prognosis on univariate
Table 3 Serum albumin and survival - female cancers
First author,
year of
publication,
place
Year of
data
collection
Study design,
Sample size
Cancer type Groups
being
compared
RR (95%Cl), p-
value
Variables adjusted for
Gupta D, 2009,
USA [77]
January 2001
to May 2006
Retrospective,
consecutive case
series, 213
Ovarian >=3.5 g/dL
<3.5 g/dL
Used as
continuous
as well
Univariate: median
survival in months
(95%CI)
Low: 7.3 (4.8 to 9.8)
Normal: 23.3 (16.5 to
30.1); p < 0.0001
Multivariate: 0.39
(0.29-0.53), <0.001
Age, BMI, CA125, tumor stage, treatment
history
Sharma R, 2008,
UK [78]
October
2003 to June
2006
Retrospective,
154
Ovarian <3.5 g/dL
>=3.5 g/dL
Univariate: 1.71
(0.92-3.18), 0.091
GPS score was
prognostic on
multivariate analysis
Tumor type, stage, grade, ascites,
debulking surgery, ALP, residual disease,
CRP
Alphs HH, 2006,
USA [79]
January 1,
1990 to June
30, 2004
Retrospective, 78 Ovarian and
primary
peritoneal
>=3.7 g/dL
<3.7 g/dL
Univariate: 0.58
(0.42-0.79), p < 0.00
Multivariate: 0.60
(0.41-0.89), p = 0.01
Age, race, BMI, Co-morbidity index,
surgeon, ASA score, tumor size,
intraoperative blood loss, ascites
Lis CG, 2003,
USA [46]
March 1993
to
December
1999
Retrospective
consecutive case
series, 180
Breast >=3.5 g/dL
<3.5 g/dL
Multivariate: 3.53,
0.0033
Abnormal breast antigen, tumor stage,
abnormal HER2/Neu readings
Wyld L 2003, UK
[80]
January 1997
to January
2002
Retrospective,
145
Breast cancer
with liver
metastases
First group
<3.0 g/dL
>=3.0 g/dL
Second
group
<3.5 g/dL
>=3.5 g/dL
Median survival in
months (95%CI)
For first group
>=3.0 g/dL = 5.86
(0.16 - 51)
<3.0 g/dL = 1.5 (0.16
- 5.13), p = 0.01
For Second group
>=3.5 g/dL = 7.0
(0.27 - 51)
<3.5 g/dL = 2.0 (0.16
- 27.2) p = 0.01
LFTs, CEA, bilirubin, age, histological
grade, ER status, metastasis, treatment
response
Clark TG, 2001,
UK [81]
01/01/1984
to 31/12/
1999
Retrospective,
1189
Ovarian Continuous
variable
Univariate: p <= 0.05
Multivariate: 0.97
(0.96, 0.99), 0.036
Age, FIGO stage, the presence
or absence of ascites, performance status,
histology, debulking, grade, CA125 and
ALP
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liver function tests (LFTs), the presence of ascites, histo-
logical grade 3 disease at primary presentation, advanced
age, estrogen receptor (ER) negative tumors, CEA of
over 1000 ng/ml and multiple vs single liver metastases.
Multivariate analysis of pretreatment variables identified
a low albumin, advanced age and ER negativity as inde-
pendent predictors of poor survival [80]. Another study
developed a prognostic model using Cox regression in
1189 primary cases of epithelial ovarian cancer and
found that the significant (P ≤ 0.05) prognostic factors
for overall survival were age at diagnosis, FIGO stage,
grade of tumor, histology (mixed mesodermal, clear cell
and endometrioid versus serous papillary), the presence
or absence of ascites, albumin, ALP, PS, and debulking
of the tumor [81].
All studies reviewed in this section were retrospective
and conducted primarily in patients with ovarian cancer.
All studies found pretreatment serum albumin to be
prognostic of cancer survival.
Multiple Cancers
Table 4 describes studies investigating the relationship
between serum albumin and cancer survival in multiple
cancer sites together. The studies are arranged chrono-
logically by the year of publication.
Table 4 Serum albumin and survival - multiple cancer sites
First author,
year of
publication,
place
Year of
data
collection
Study design,
Sample size
Cancer type Groups
being
compared
RR (95%Cl), p-value Variables adjusted for
Penel N, 2008,
USA [82]
October
1997 to
October
2002
Retrospective
consecutive case
series, 148
Breast, colon, rectum,
head and neck, lung,
others
>=3.8 g/dL
<3.8 g/dL
Univariate:
Median overall
survival (days)
<38 g/l: 91 (1-2421)
>=38 g/l: 363 (296-
429), p = 0.00001
Multivariate: 2.51
(1.51-4.18); 0.0001
Primary site, liver metastases, other
viscera metastases, BMI, lymphocyte
count, granulocyte count
Lam PT, 2007,
Hongkong
[12]
January to
December
2002
Prospective
cohort, 170
Lung, liver, lower
gastrointestinal tract,
breast,
gynecological,
haematological,
nasopharyngeal,
prostate, unknown,
others
Continuous
variable
Univariate: 0.94 (0.91-
0.96), <0.001
Multivariate: 0.95
(0.92-0.98), 0.001
Demographic data, tumor
characteristics, blood parameters,
functional status, comorbidities, total
symptom score, and psychosocial
parameters
Santarpia L,
2006, Italy [83]
January
1996 to
September
2003
Retrospective,
152
Stomach, ovaries,
colorectal,
endometrium,
breast, ileum,
gallbladder,
pancreas, kidney,
skin, prostate,
abdominal sarcoma,
unknown
Mean (SD)
2.8 +/-0.6
g/dL
3.1+/- 0.5
g/dL
3.3+/- 0.6
g/dL
Survival in days
For 2.8 +/-0.6
g/dL = <30 days
For 3.1+/- 0.5
g/dL = 30-90 days
For 3.3+/- 0.6
g/dL = >90 days
p = 0.001
Age, gender, height, weight, BMI,
hemoglobin, lymphocyte count,
cholesterol, CHE, KPS score, pain,
ascites, vomiting
Pasanisi F,
2001, Italy [84]
1995-1999 Retrospective
consecutive case
series, 76
Stomach,
colorectal, ovary,
others
Mean (SD)
3.13 +/- .51
g/dL
3.57 +/- .43
g/dL
Survival in months
For 3.13 +/- .51 g/dL
<= 3 months
For 3.57 +/- .43 g/dL
> 3 months
P = 0.002
Age, weight, BMI, hemoglobin,
lymphocyte count, cholesterol, pain
and ascites
Vigano A,
2000, Canada
[85]
July 1, 1996,
to
December
31, 1998
A prospective
cohort of 227
consecutive
patients
Breast,
gastrointestinal,
lung
>=3.5 g/dL
<3.5 g/dL
Univariate: 1.9
(1.4-2.8), <0.01
Multivariate: 7.3
(2.9-18.1)
Lung primary tumor, presence of
liver metastases, tumor burden, co
morbidity, performance status,
weight loss, lymphocyte count,
nausea, LDH
Maltoni M,
1997, Italy [86]
NA Prospective
consecutive case
series, 519
Solid tumors
excluding renal
cancer and
hematological cancer
Normal: 3.3-
5.5 g/dL
Low: 2.7-3.2
g/dL
Very low:
<=2.6 g/dL
Univariate: p = 0.0015
Median length of
survival (days):
Normal =40.0
low = 29.5
Very low = 24.0
months
Total WBC, neutrophil percentage,
lymphocyte percentage, proteinuria,
pseudocholinesterase
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cancer patients screened for Phase1 trials. The univariate
analysis identified PS ≥ 1, BMI < 20 kg/m2, other primary
sites (excluding breast, lung, head and neck and colon and
rectum), presence of liver metastases, presence of other
visceral metastases, serum albumin <38 g/l, lymphocyte
count <700/mm3 and granulocyte count >7500/mm3 as
poor prognostic factor for overall survival. The Cox model
identified serum albumin and lymphocyte count as inde-
pendent prognostic factors [82]. A study done to identify
potential factors affecting survival in patients with
advanced cancer in a local palliative care unit found age,
number of involved metastatic sites, serum albumin, PS
score, and Edmonton Symptom Assessment System score
were independent prognosticators [12]. Another study
done in patients with carcinomatosis on home parenteral
nutrition found traditional parameters (PS, albumin, pain,
and vomiting) and cholinesterase level to be useful survival
predictors [83]. Clinical, anthropometric, hematologic, and
biochemical variables, evaluated immediately before start-
ing nutritional treatment, were related to survival in 76
terminal-cancer patients with irreversible bowel obstruc-
tion receiving home parenteral nutrition. With regard to
bivariate and multivariate analyses, the linear correlation
indicated that survival was associated with albumin (r =
0.489, P = 0.001) and hemoglobin (r =0 . 3 0 0 ,P =0 . 0 0 8 )
but not with age, weight, BMI, lymphocyte count, or cho-
lesterol [84].
A study done to establish the predictors of survival in
patients with terminal cancer found that shorter survival
was independently associated with a primary tumor of
the lung (vs breast and gastrointestinal tract combined),
liver metastases, moderate to severe co morbidity levels
(vs absent-to-mild levels), weight loss of greater than 8.1
kg in the previous 6 months, serum albumin levels of
less than 3.5 g/dL, lymphocyte counts of less than 1 ×
10
9/L, serum LDH levels of greater than 618 U/L, and
clinical estimation of survival by the treating physician
of less than 2 months (vs 2-6 and >6 months) [85]. A
multicenter study assessed the role of 13 hematological
and urinary parameters in 530 terminally ill cancer
patients. A poor prognosis was predicted by high total
WBC count, high neutrophil percentage, low lympho-
cyte percentage, low serum albumin levels, low pseudo-
cholinesterase levels, and high proteinuria [86].
Studies reviewed in this section were conducted in
patients with a wide range of cancer types including
breast, colon, head and neck, lung, liver and gynecological.
All studies found pretreatment serum albumin to be prog-
nostic of cancer survival.
Other Cancer Sites
Table 5 describes studies investigating the relationship
between serum albumin and cancer survival in other
less common cancer sites. The studies are arranged
chronologically by the year of publication.
A study analyzing a group of 61 patients with soft tis-
sue sarcomas found advanced stage, high tumor grade,
irresecability, and serum albumin as independent prog-
nostic factors of survival upon multivariate analysis [87].
A study investigated how lymphopenia and low serum
albumin could predict prognosis of patients with carci-
noma of unknown primary (CUP). The results from
multivariate analysis showed that patients who had a PS
>= 2 (using the World Health Organization scale), a
high overall comorbidity score (on the Adult Comorbid-
ity Evaluation 27), liver metastasis, elevated serum LDH
levels, lymphopenia (defined as an absolute lymphocyte
count >=0.7 × 10
9/L), and low serum albumin levels had
a worse prognosis. Lymphopenia and low serum albu-
min levels were identified as 2 new independent markers
of prognosis in patients with CUP [47]. A study con-
ducted to identify the prognostic factors that specifically
predict survival of patients with localized aggressive
Non Hodgkin’s Lymphoma (NHL), found incomplete
response, low serum albumin, bulky disease (>10 cm),
and high grade histology to be independent predictors
of survival [88]. In a study on head and neck cancer
patients, age, TNM tumor stage, functional class, systo-
lic and diastolic blood pressure, BMI, and serum albu-
min concentration were evaluated as predictors of
survival. Patients with stage IV or recurrent squamous
cell carcinoma could be stratified by either serum albu-
min concentration or by age into 2 groups with a med-
ian survival of 1 or 2 years [89]. In another study a
number of variables were analyzed to identify factors
that might predict the survival time in renal carcinoma.
A number of factors correlated to survival time in uni-
variate analysis, including solitary versus multiple metas-
tases, serum albumin and DNA ploidy, but after Cox
multivariate analysis their significance was lost [90]. To
determine whether serum albumin levels, before first
surgery, predict time until death, 24 glioblastoma multi-
forme patients were studied. Patients with presurgical
serum albumin levels below 3.4 g/dL survived an aver-
age (median) of 62 days (95% confidence interval (CI):
34, 135 days) after surgery. Those with serum albumin
levels of at least 3.4 g/dL survived an average of 494
days (95% CI: 241, 624 days). It was concluded that pre-
surgical serum albumin levels can be used to evaluate
the success of randomization of clinical trials for glio-
blastoma multiforme therapies [91]. Another showed
that raised serum LDH levels, hypoalbuminemia and
distant metastases at diagnosis were independent
adverse prognostic factors in 116 patients with Ewing’s
sarcoma [92]. A study done with an objective of deter-
mining prognostic factors for survival in renal cancer
patients found the following variables to be statistically
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free interval (DFI), PS, stage at diagnosis, grading,
nephrectomy, sites of metastases, blood hemoglobin,
serum albumin, calcium, LDH, ALP [93].
Most of the studies reviewed in this section were ret-
rospective and conducted in a wide range of cancer
types including renal, head and neck, glioblastoma mul-
tiforme, NHL, soft tissue sarcoma, Ewing’s sarcoma and
unknown. All studies found pretreatment serum albu-
min to be prognostic of cancer survival.
Discussion
Ecological and observational studies suggest that low
serum albumin is associated with higher mortality from
cancer. Research conducted over the last decade or so
has demonstrated that serum albumin levels (either con-
sidered alone or in combination with other parameters)
can provide useful prognostic information in a variety of
cancers. For example, some studies have used an inflam-
mation based score, which is derived from the acute-
p h a s ep r o t e i n sC R Pa n da l b u m i na n di st e r m e dt h e
Table 5 Serum albumin levels and survival - other cancer sites
First author,
year of
publication,
place
Year of
data
collection
Study
design,
Sample size
Cancer type Groups being
compared
RR (95%Cl), p-value Variables adjusted for
Barreto-
Andrade JC,
2009, Mexico
[87]
January
1986 to
May 2006
Retrospective,
61
Soft Tissue
Sarcoma
Low <3.5 g/dL
Normal >=3.5
g/dL
Univariate: p = 0.03
Multivariate: p = 0.02
Age, sex, obesity, previous biopsy
performed, histology, site histologic
grade, stage, tumor resectability,
tumor size, performance status,
surgical risk
Seve P, 2006,
France [47]
January 1,
1998 to
December
31, 2004
Retrospective
consecutive
case series,
317
Unknown
Primary
Low <3.5 g/dL
Normal >=3.5
g/dL
Univariate: Median survival in
days
Low: 62; Normal: 318; p <
0.0001
Multivariate: 2.70 (1.79-4.07),
<.0001
Age, sex, ACE-27 score, No. of sites,
liver metastasis, peritoneal mets, PS,
LDH, ALP, hemoglobin, platelets
Alici S, 2003,
Turkey [88]
1989 to
1998
Retrospective,
110
Non-
Hodgkin’s
Lymphoma
Normal
Low
Univariate: p = 0.005
Multivariate: p = 0.022
Age, sex, stage, PS, B symptoms,
treatment regimen, remission status,
histology, bulky disease, LDH, ESR,
extranodal involvement
Medow MA,
2002, USA [89]
July 1993
to June
1997
Retrospective
consecutive
case series,
406
Head and
neck
<3.85 g/dL
>=3.85 g/dL
TNM stage IV or recurrent
disease
Median survival:
<3.85 g/dL: 404 days (286-532
days),
>=3.85 g/dL: 625 days (536-
1032 days)
Age, tumor stage, self-reported
functional class, systolic blood
pressure, diastolic blood pressure,
and BMI
Ljungberg B,
2000, Sweden
[90]
April 1982
to
February
1999
Retrospective
consecutive
case series,
106
Renal cell Continuous
variable
Univariate: NA, p = 0.063
Multivariate: 1.01 (0.45 - 2.28),
0.96
Age, gender, tumor size, PS, solitary
metastases, calcium, ESR, nuclear
grade, DNA ploidy and vein invasion
Schwartzbaum
JA, 1999, USA
[91]
February 1,
1993 to
December
31, 1995
A
convenience
sample, 24
Glioblastoma
multiforme
1
st Quartile
(2.6-3.1 g/dL)
2
nd Quartile
3
rd Quartile
4
th Quartile
(3.9-4.4 g/dL)
Multivariate:
2
nd= 1.2
3
rd= 0.1
4
th =0.1
p = 0.007
Age, sex, chemotherapy, serum iron,
radiation
Aparicio J,
1998, Spain
[92]
1970 to
1993
Retrospective,
116
Ewing’s
sarcoma
Low: <=3.5 g/
dL
Normal: >3.5
g/dL
Univariate: 5 year survival 48%
in normal and 7% in low;
median survival 52 months in
normal and 6 months in low, p
< 0.0001
Multivariate: p = 0.001
Age, sex, tumor site, maximum
tumor diameter, extent of disease,
PS, duration of symptoms before
diagnosis, systemic symptoms,
leukocytes and hemoglobin, ESR,
LDH, histologic pattern, percent of
tumor necrosis on the initial biopsy
specimen
Citterio G,
1997, Italy [93]
1988
onwards
Retrospective
consecutive
case series,
109
Renal cell NA Univariate: p < 0.01 Age, sex, DFI, PS, stage at diagnosis,
grading, number and type of
metastatic sites, nephrectomy, blood
levels of hemoglobin, creatinine,
calcium, LDH, ferritin, ALP,
triglycerides
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Page 12 of 16GPS. The GPS has been defined as follows: patients with
both an elevated CRP (>10 mg/l) and hypoalbuminemia
(<3.5 g/dL) are allocated a score of 2; patients in whom
only one of these biochemical abnormalities is present
are allocated a score of 1; patients in whom neither of
these abnormalities is present are allocated a score of 0.
With CRP > 10 mg/L and serum albumin levels >=3.5
g/dL the HR was 2 (CI = 1.47-2.70 and p < 0.001)
[3,48,51,54]. In this paper, we systematically review all
available epidemiologic literature on the relationship
between pretreatment serum albumin and cancer
mortality.
Of the 29 studies reviewed on cancers of the gastroin-
testinal tract, 23 studies were retrospective and 6 were
prospective. Majority of the studies were conducted in
colorectal and hepatocellular cancer. The sample size
studied ranged from 51 to 1367. Serum albumin was
either used as a categorical variable (with 3.5 g/dL as
the most commonly used cut off) or continuous vari-
able. Some studies used different cut offs such as 4 g/dL
[49] and 4.15 g/dL [57]. Age, sex, white cell count, stage
of the tumor, tumor site, PS, BMI and LFTs were the
most commonly adjusted variables in the multivariate
analysis. All except three studies [58,59,66] found higher
serum albumin levels to be associated with better survi-
val in multivariate analysis.
Of the 10 studies reviewed on lung cancer, 4 were
prospective and 6 were retrospective. 7 studies were
done in NSCLC patients, 2 in SCLC and 1 study
included both NSCLC and SCLC patients. The sample
size studied ranged from 101 to 411. Serum albumin
w a se i t h e ru s e da sac a t e g o r i c a lv a r i a b l e( w i t h3 . 5g / d L
as the most commonly used cut off) or continuous vari-
able. Some studies used different cut offs such as 3.4 g/
d L[ 7 3 ]a n d4g / d L[ 7 6 ] .A g e ,s e x ,s t a g eo ft h et u m o r ,
PS, metastasis and LFTs were the most commonly
adjusted variables in the multivariate analysis. All studies
excepting one [4] concluded that higher serum albumin
levels were associated with better survival.
Six studies were reviewed on female cancer patients.
Four were conducted in ovarian and 2 in breast cancer.
All 6 studies were retrospective. The sample size studied
ranged from 78 to 1189. Serum albumin was either used
as a categorical variable (with 3.5 g/dL as the cut off) or
continuous variable. Age, stage of the tumor, BMI, PS,
metastasis, treatment history and LFTs were the most
commonly adjusted variables in the multivariate analysis.
Consistent with studies reviewed under gastrointestinal
and lung cancers, lower levels of serum albumin were
associated with poor survival in all 6 studies.
Six studies were reviewed on patients with multiple
cancer types. Of these, 3 studies were retrospective and
3 prospective. The sample size studied ranged from 76
to 519. The studies used a variety of albumin cut offs,
the most commonly used being 3.5 g/dL. Age, primary
site, stage of the tumor, BMI, blood counts, metastasis,
comorbidities, PS and LFTs were the most commonly
adjusted variables in the multivariate analysis. Lower
levels of serum albumin were associated with poor sur-
vival in all studies.
Finally, we reviewed 8 studies conducted on patients
with other cancer sites. Two studies were done on renal
cancer patients while one each on head and neck can-
cer, glioblastoma multiforme NHL, soft tissue sarcoma,
Ewing’s sarcoma and unknown primaries. Of these 8
studies, 7 were retrospective and 1 was based on a con-
venience sample. One study used an albumin cut off of
3.85 g/dL [89]. Age, primary site, stage of the tumor,
BMI, blood counts, metastasis, treatment regimens, PS
and LFTs were the most commonly adjusted variables
in the multivariate analysis. Lower levels of serum albu-
min were found to be associated with poor survival in
all studies.
The advantages and disadvantages of serum albumin
as an indicator of nutritional status deserve some men-
tion. Serum albumin level is not only a window into the
patient’s nutritional status but also a useful factor for
predicting patient prognosis [63]. Lower levels of serum
albumin are indicative of an ongoing systemic response
that causes the loss of these proteins [50,67]. The poten-
tial advantage of serum albumin level as a pretreatment
prognostic factor in cancer patients is that it is inexpen-
sive, reproducible and powerful [50]. When clinical trials
are conducted, the success of randomization can be
evaluated by comparing pretreatment serum albumin
levels in the two arms [91]. Finally, because low levels of
serum albumin are associated with poor outcome in
cancer patients, perhaps serum albumin can be used as
an independent indicator of the need for aggressive
nutrition intervention [46]. Among the main disadvan-
tages, the interpretation of serum albumin is often diffi-
cult because non-nutritional factors, such as hydration
state and disease process, can obscure the effects of
actual nutrient deprivation [94]. Furthermore, serum
albumin has a relatively long half-life, thus, assessing
changes in the nutritional status over a short period of
time is challenging [77].
Like most other systematic reviews, this review also
suffers from potential publication bias. In general, this
bias exists when studies reporting positive associations
are more likely to get published. It remains possible that
some studies containing valuable data might have gone
undetected. Since we restricted this systematic review to
include studies published in English only, it is possible
that language bias might have affected our conclusions.
Despite these limitations, we believe that the extensive
available literature reviewed here demonstrates a strong
prognostic role of serum albumin in predicting cancer
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Page 13 of 16survival. Future studies should evaluate the association
between serum albumin levels and patient quality of life.
Studies should also prospectively evaluate whether nutri-
tional intervention could have a positive impact on
serum albumin levels with a subsequent improvement in
patient survival.
In summary, pretreatment serum albumin levels pro-
vide useful prognostic significance in cancer. Accord-
ingly, serum albumin level could be used in clinical
trials to better define the baseline risk in cancer patients.
A critical gap for demonstrating causality, however, is
the absence of clinical trials demonstrating that raising
albumin levels by means of intravenous infusion or by
hyperalimentation decreases the excess risk of mortality
in cancer.
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